CANTON, Mich. (3/21/2023) – MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in innovative clinical trial delivery solutions, Dr. Breitfeld and Dr. Zeiher’s additions as advisors expand MMS’ therapeutic area expertise to support growth in different therapeutic areas.
“We are pleased to welcome Dr. Breitfeld and Dr. Zeiher to our Scientific Advisory Board,” said Uma Sharma, Ph.D., CEO of MMS. “At MMS, we work with our sponsors to support the development of groundbreaking therapies and bring them to market. Both Bernie and Phil bring much experience in different therapeutic areas and advanced drug development to guide our sponsors and teams with their expertise for many upcoming challenges.”
Dr. Breitfeld has nearly 20 years of experience in the pharmaceutical industry and has led development and project teams focusing on Phase 1, Proof of Concept, and Pivotal trials in oncology. He has pharmaceutical development experience in solid tumor and malignant hematology, including leading oncology development at small biotechs and midsized global pharma companies.
Prior to MMS, Dr. Breitfeld developed and led the Oncology Center of Excellence at IQVIA, the matrix organization that drives the long-term business agenda for oncology at the organization.
“I’m excited to draw from my years of oncology experience to help MMS provide solutions for Sponsors and patients,” said Dr. Breitfeld. “I’m joining a well-respected team of advisors and looking forward to working with them at such an innovative organization.”
Dr. Zeiher has led the development of products in critical care, pain, immunology and infectious diseases. He was involved in and oversaw the approval of over 15 products.
Over the course of his 20 years in the industry, he has held leadership and executive responsibility positions at Astellas, Pfizer and Lilly, including board memberships, Chief Medical Officer and President of Development.
“MMS does great work bringing life-changing therapies to patients,” said Dr. Zeiher. “I’m passionate about addressing patients’ unmet needs, and I’m excited to work for an organization where I can use my years of experience to fulfill that goal.”
Both join a team of industry-leading advisors at MMS. Learn more here.
MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.